All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Themis Bioscience GmbH has announced positive phase II results for its vaccine against Chikungunya virus, as it moves to complete an IPO later this week to raise up to €55 million (US$62.6 million) to fund the launch of a pivotal phase III trial.